Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain
Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previously received approval by the Spanish Ethics Committee. With both regulatory and ethical approval all prerequisites to start the trial in Spain are met. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will